- Post-Effective Amendment to Registration Statement (POS AM)
13 3월 2009 - 12:01AM
Edgar (US Regulatory)
As
filed with the Securities and Exchange Commission on March 12, 2009
Registration
No. 333-56512
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
POST-EFFECTIVE
AMENDMENT NO. 1 TO
FORM
S-3
REGISTRATION
STATEMENT
UNDER
THE SECURITIES
ACT
OF 1933
SYNVISTA
THERAPEUTICS, INC.
(Exact
name of registrant as specified in its charter)
Delaware
|
13-3304550
|
(State
or other jurisdiction
|
(IRS
Employer
|
of
incorporation or organization)
|
Identification
Number)
|
221
West Grand Avenue
Montvale,
New Jersey
(Address
of Principal Executive Offices)
|
07645
(Zip
Code)
|
|
|
Noah
Berkowitz, M.D., Ph.D.
President
and Chief Executive Officer
|
Copies
to:
Megan
N. Gates, Esq.
|
Synvista
Therapeutics, Inc.
|
Mintz,
Levin, Ferris, Glovsky & Popeo, P.C.
|
221
West Grand Avenue
|
One
Financial Center
|
Montvale,
NJ 07645
|
Boston,
MA 02111
|
(201)
934-5000
|
(617)
542-6000
|
(Name,
address, including zip code, and telephone
number,
including area code, of agent for service)
|
|
Not
Applicable
|
(Approximate
date of commencement of proposed sale to the
public)
|
DEREGISTRATION
OF UNSOLD SECURITIES
On March 5, 2001, Synvista
Therapeutics, Inc., formerly known as Alteon Inc. (the “Company”), filed
a Registration Statement on Form S-3, as amended (File No. 333-56512)
(the “Registration Statement”), to register $50,000,000 of shares of the
Company’s common stock, par value $0.01 per share (the “Common
Stock”). This offering has been terminated because the Company
intends to deregister its Common Stock under the Securities Exchange Act of
1934, as amended. Consequently, in accordance with an undertaking
made by the Company in the Registration Statement to remove from registration,
by means of a post-effective amendment, any of the securities that remain unsold
at the termination of the offering, the Company hereby removes from registration
the securities of the Company that are registered but unsold under the
Registration Statement.
SIGNATURES
Pursuant to the requirements of the
Securities Act of 1933, the registrant certifies that it has reasonable grounds
to believe that it meets all the requirements for filing on Form S-3 and has
duly caused this Post-Effective Amendment No. 1 to its Registration Statement to
be signed on its behalf by the undersigned, thereunto duly authorized, in the
City of Montvale, State of New Jersey on March 12, 2009.
|
SYNVISTA
THERAPEUTICS, INC.
|
|
|
|
|
|
|
By:
|
/s/ Noah Berkowitz, M.D.,
Ph.D.
|
|
|
|
Noah
Berkowitz, M.D., Ph.D.
|
|
|
|
President
and Chief Executive Officer
|
|
|
|
|
|
Pursuant to the requirements of the
Securities Act of 1933, this Post-Effective Amendment No. 1 to the Registration
Statement has been signed by the following persons in the capacities and on the
dates indicated.
Signature
|
|
Title
|
|
Date
|
|
|
|
|
|
|
|
|
|
|
/s/ Noah Berkowitz, M.D.,
Ph.D.
|
|
President,
Chief Executive
|
|
March
12, 2009
|
Noah
Berkowitz, M.D., Ph.D.
|
|
Officer
and Director
|
|
|
|
|
|
|
|
|
|
|
|
|
/s/ Wendy A. Milici
|
|
Principal
Financial Officer and
|
|
March
12, 2009
|
Wendy
A. Milici
|
|
Principal
Accounting Officer
|
|
|
|
|
|
|
|
|
|
|
|
|
/s/ John F. Bedard
|
|
Director
|
|
March
12, 2009
|
John
F. Bedard
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
/s/ William Federici
|
|
Director
|
|
March
12, 2009
|
William
Federici
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
/s/ Mary C. Tanner
|
|
Director
|
|
March
12, 2009
|
Mary
C. Tanner
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
/s/ Wayne P. Yetter
|
|
Director
|
|
March
12, 2009
|
Wayne
P. Yetter
|
|
|
|
|
S.Y. Bancorp (AMEX:SYI)
과거 데이터 주식 차트
부터 10월(10) 2024 으로 11월(11) 2024
S.Y. Bancorp (AMEX:SYI)
과거 데이터 주식 차트
부터 11월(11) 2023 으로 11월(11) 2024